In addition, drugs targeting ROS1 re-arrangement have already approved and obtained favorable effects in NSCLC patients [76], although ROS1 mutation and increased copy numbers were detected in ES-RMS, but no ROS1 re-arrangement was detected, therefore, we still don’t know whether targeting ROS1 mutation or increased copy numbers will be valuable. Here, ROS1 is linked to non-small cell lung carcinoma.